For instance, CDK9 has been proposed as an attractive drug target for acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, hepatocellular carcinoma (HCC), prostate cancer, and also several inflammatory diseases (6, , , , , –12). This evidence concerns the gene CDK9 and hepatocellular carcinoma.